Madrigal Pharmaceuticals, Inc.
General ticker "MDGL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $7.7B (TTM average)
Madrigal Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 52.8%.
Estimated limits based on current volatility of 1.8%: low 422.80$, high 439.90$
Factors to consider:
- Total employees count: 528 (+40.4%) as of 2024
- Top business risk factors: Labor/talent shortage/retention, Regulatory and compliance, Strategic risks and growth management, Product development risks, Manufacturing risks
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [260.82$, 698.23$]
- 2026-12-31 to 2027-12-31 estimated range: [134.95$, 400.10$]
Financial Metrics affecting the MDGL estimates:
- Negative: with PPE of -45.4 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -1.45 <= 0.01
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 0.25 > -0.63
- Positive: Inventory ratio change, % of -8.66 <= -0.75
- Positive: 42.68 < Shareholder equity ratio, % of 47.85 <= 64.29
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0.17 <= 0.73
Short-term MDGL quotes
Long-term MDGL plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $180.13MM | $958.40MM |
| Operating Expenses | $380.50MM | $678.01MM | $1,258.50MM |
| Operating Income | $-380.50MM | $-497.88MM | $-300.10MM |
| Non-Operating Income | $6.87MM | $31.98MM | $11.81MM |
| Interest Expense | $12.71MM | $14.67MM | $22.31MM |
| R&D Expense | $272.35MM | $236.72MM | $388.52MM |
| Income(Loss) | $-373.63MM | $-465.89MM | $-288.28MM |
| Profit(Loss)* | $-373.63MM | $-465.89MM | $-288.28MM |
| Stockholders Equity | $405.33MM | $754.38MM | $602.69MM |
| Inventory | $0.00MM | $34.07MM | $74.84MM |
| Assets | $640.55MM | $1,042.25MM | $1,259.59MM |
| Operating Cash Flow | $-324.23MM | $-455.57MM | $-189.55MM |
| Capital expenditure | $1.48MM | $1.46MM | $0.47MM |
| Investing Cash Flow | $-502.52MM | $-274.39MM | $32.32MM |
| Financing Cash Flow | $595.12MM | $735.06MM | $255.98MM |
| Earnings Per Share** | $-19.99 | $-21.90 | $-12.85 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.